Summary.-The in vitro chemosensitivity of primary monolayer cultures of human ovarian tumours to a wide range of chemotherapeutic agents has been determined using 3H-leucine incorporation as an index of cytotoxicity. Of 67 specimens received, 35 have been successfully cultured and tested for chemosensitivity. Drugs tested included alkylating agents, antibiotics, antimitotics, antimetabolites and progestogens. The overall incidence of efficacy of the drugs corresponded with the incidence which might be expected from data on the clinical response rates produced by the various drugs. Cultures from the tumour cells of treated patients generally showed greater resistance than tumours of untreated patients. Correlation between in vitro results and in vivo response was positive in all 8 patients receiving first-line chemotherapy and in 57oo (4/7) patients receiving second-line chemotherapy.
THE FIRST reported work on the use of in vitro predictive tests for cancer chemotherapy in the individual was in 1957 (Wright et al., 1957) and subsequently a number of studies have been undertaken to evaluate the usefulness of such tests. Several workers have used short-term monolayer cultures for determination of in vitro chemosensitivity ofhuman tumours (Berry et al., 1975; Dendy et al., 1970; Holmes & Little, 1974; Limburg & Heckman, 1968) and good correlation between in vitro chemosensitivity and clinical response has been reported (Holmes & Little, 1974; Limburg & Heckman, 1968; Wheeler et al., 1974) .
Recently, a microtest plate system for cell-line growth and subsequent determination of chemosensitivity, using 3H-leucine incorporation as an end-point for cell death, has been described (Freshney et al., 1975) . The use of microtest plates readily permits multiple drug testing, and the present investigation was undertaken with the aims of (i) using primary cultures from human ovarian tumours to screen a wide number of agents with potential clinical activity against ovarian carcinoma, (ii) on that basis to use agents with marked in vitro activity in the treatment of ovarian cancer, and (iii) to correlate the in vitro and in vivo data.
MATERIALS AND METHODS
Tumnouar material.-Material from patients with histologically proven ovarian carcinoma was used. This included 40 solid tumours, 23 ascitic fluids and 4 pleural fluids. The presence of malignant cells in the samples received in the laboratory was checked histologically. Cultures were not used for sensitivity testing if fibroblasts, recognized as areas of spindleshaped cells arrayed in parallel, were present in large numbers, or if the growth pattern was not characteristic of ovarian tumour cells as described in the literature (Joachim et al., 1974 ).
Cell preparation.-Sterile tumour biopsy samples were transported to the laboratory in Hanks' balanced salt solution with antibiotics. Necrotic and capsular material was dissected away and the tissue minced finely. After washing in phosphate-buffered saline (PBS), the mince was transferred to a conical (Connors et al., 1974) , and was tested to avoid the neces-sity for in vitro activation of the parent compound.
All drug solutions were prepared immediately before use, except actinomycin D, vinblastine and vincristine, which were stored up to 10 days at 4°C. Chlorambucil, hexamethylmelamine, 6-mercaptopurine, norethisterone acetate, medroxyprogesterone acetate and methyl prednisolone acetate were suspended in 0-5% methyl cellulose to give a stock drug concentration of 1 mg/ml. This concentration of methyl cellulose was found to be non-toxic to cells. All other drugs were dissolved in growth medium to give a stock concentration of 1 mg/ml. Drugs were tested at 2-3 concentrations in loglo increments; triplicate wells were used for each concentration and triplicate controls of growth medium only were included for each drug.
Drugs were tested over a concentration range which included levels achievable in the patient; in the absence of pharmacokinetic data, drugs were tested at a maximum concentration of 10-1 mg/ml. Concentrations tested, together with plasma levels, are shown in Table I for all drugs used. Cultures were exposed to the drugs for 48 h and then allowed to recover for 24 h in medium only before determination of the inhibitory effects of the drugs.
Cytotoxicity determination. In earlier cultures, inhibition of growth was determined by morphological assessment of the degree of drug damage on haematoxylin-and eosinstained monolayers. Inhibition of 3H-leucine incorporation was used on later cultures as an index of drug effect. At the end of the 24 h recovery, 100 ,ul of 20puCi/ml 3H-leucine (L-4-5-3H-Leucine, Radiochemical Centre) was added to each well and the plates were incubated for 3 h at 37°C. The amount incorporated was assayed by previously described methods (Freshney et al., 1975) . The percentage inhibition produced by each drug and drug concentration was calculated, and drugsensitivity histograms were plotted for individual patients. Standard errors of the means ranged from 1% to 100% routinely, with occasional values of + 15%. Reproducibility between duplicate plates was in the same range. It was not possible to test the day-to-day reproducibility for surgical specimens, but results obtained with cell lines using the same assay system indicated that inter-experiment variation was usually in the same range (Wilson, unpublished data) .
Clinical data
Thiotepa was routinely used as a single agent, 30 mg being administered i.m. at 3-weekly intervals when the platelet count was > 105/mm3. When the platelet count was less than this, thiotepa was withheld and 50 mg Decadurabolin was administered. The two combination regimes were also given once every 3 weeks, the two regimes being 5-fluorouracil (750 mg), actinomycin D (0 5 mg) and thiotepa (30 mg), or vinblastine (2 mg), actinomycin D (0 5 mg) and thiotepa (30 mg), known as FAT and VAT respectively. Patients receiving combination therapy also received radiotherapy.
Responses were considered complete when there was alleviation of symptoms, disappearance of palpable masses and absence of ascitic fluid accumulation for more than 3 months. Responses were considered partial when there was alleviation of symptoms, either subjectively or objectively for more than 3 months with first-line chemotherapy (first choice of chemotherapy) or more than 1 month with second-line chemotherapy (chemotherapy given after relapse on first-line chemotherapy).
RESULTS
Of 67 specimens received, 35 The tumour specimens exhibited considerable variation in their degree of sensitivity to the drugs in vitro. Experimental variation was usually less than ± 15%, but considerably greater variations between specimens were found at given drug concentrations. Variations in sensitivity to the different drugs are shown The range of sensitivity to alkylating agents shown by cultures of tumouir cells from untreatedl (A) and treated (B) patients. All concentrations are in mg/ml. CMB chlorambucil; PAM phosphoramide mustard; CIS cis-platinum; MUS mustine; TSPA thiotepa; TREO treosulfan.
in Figs 1-3; tumours from untreated and treated patients are shown in (A) and (B) respectively of each figure.
Alkylating agents
Results obtained with alkylating agents are shown in Fig. 1 . Cultures from treated and untreated patients showed maximal sensitivity to the highest concentration of cis-platinum and phosphoramide mustard, and most showed maximal sensitivity to the highest concentration of chlorambucil, mustine, thiotepa and treosulfan. Cultures were also maximally sensitive to the middle concentration of cis-platinum, but showed considerable variations in their sensitivity to the lowest concentration of this drug, and to the two lower concentrations of the other alkylating agents.
All treated patients had received thiotepa, either singly or in combination. At 10-2 mg/ml of thiotepa there was no difference in the range of percentage inhibition values between the treated and untreated groups, but there was a difference at 10-3 mg/ml which had the effect Fig. 1 ; concentration shlown in mg/ml.
-indicates these drugs were not tested. O boxed-in figures represent tumours classifie(d as sensitive to thtat of steepening the dose-response curve in drug at v the treated group. With phosphoramide curred al mustard both treated and untreated point (seE patients' tumours showed resistance at was seen 10-3 mg/ml when a 50% cut-off point was (10, 11).
used; untreated tumours still showed a in 2 unti variation between 0 and 50% inhibition treated (] at this concentration, whilst tumours from sensitivit treated patients were consistent in showing showed c < 10% inhibition with this drug at this mustard concentration, with a single exception. treosulfai Similar differences between treated and parallel r untreated groups were not apparent for phoramid the other alkylating agents tested. lowered Individual patients' tumours were thiotepa looked at for their spectrum of sensitivity mustard, to alkylating agents; these results are group sti shown in Table II which the widest distribution ocbove and below the 50% cut-off e Fig. 1 ). Sensitivity to all agents i in only 2 untreated patients Resistance to all agents was seen reated patients (4, 5) and in one 14) . In untreated patients without ;y to thiotepa, drugs which still -ytotoxicity were phosphoramide (3, 9), cis-platinum (6, 9, 13) and n (12). Cultures generally showed resistance or sensitivity to phosle mustard and thiotepa. Despite sensitivity to 10-3 mg/ml of and 10-2 mg/ml phosphoramide some tumours from the treated ill showed sensitivity to chloram-5), treosulfan (20, 21) and cis-(20, 22). No clear-cut correlation between histology and drug sensitivity was found except for cyclophosphamide, for which only 1/4 well-differentiated tumours showed sensitivity, whilst 5/7 poorly differentiated tumours showed sensitivity.
Antimetabolites
The spectrum of sensitivity to the antimetabolites tested is shown in Fig. 2 . 5-Fluorouracil and Cytosar showed the greatest cytotoxicity in the untreated group. Methotrexate was inhibitory at the 50% level in only 3 cultures from the untreated group; because of its phase specificity, increasing concentrations did not generally increase the level of inhibition. 6-Mercaptopurine was cytotoxic against only 2 tumours at 10-1 mg/ml. Comparison of the curves for treated and untreated patients showed an overall decrease in sensitivity in the treated group to all antimetabolites tested.
Antimitotics
The spectrum of sensitivity to vincristine and vinblastine is shown on the left of Fig. 3 . Both drugs showed similar activity against untreated tumours; as expected with phase-specific agents, the level of inhibition was dose-independent for most tumours, though this was more frequent with vinblastine than vincristine. In treated tumours vincristine showed considerably less activity, all tumours being resistant, but vinblastine, whilst less active, was still cytotoxic to some tumours from treated patients.
Antibiotics
The spectrum of sensitivity to the antibiotics is shown on the right of Fig. 3 . Although the peak plasma concentration of actinomycin D was -7.5 x 10-5 mg/ml (Tattersall et al., 1975) , the drug was routinely tested at 5 x 10-8, 5 x 10-9 and 5 x 10-10 mg/ml because of its extreme in vitro cytotoxicity at higher concentrations. Tumours were sensitive ( > 500/o inhibition) at all concentrations tested, with only one exception. Tumours from patients treated with FAT or VAT still displayed in vitro sensitivity, though this was reduced in 2 patients.
Adriamycin showed marked activity at 10-2 and 10-3 mg/ml in the untreated group, which was considerably reduced in treated tumours. Bleomycin also showed more activity against untreated tumours than against treated tumours.
Miscellaneous agents
Of the other agents tested routinely no useful activity against tumour cells was demonstrated by procarbazine or warfarin at concentrations of 10-1 mg/ml. Norethisterone acetate was effective against 10/15 specimens at 10-1 mg/ml but only against 2/18 at 10-2 mg/ml. At concentrations of 10-1 mg/ml medroxyprogesterone acetate and methylprednisolone acetate were effective against 4/10 specimens at levels of inhibition of 30-50%.
Correlation of in vitro results with clinical response for individual patients
Patients from whom tumour samples were obtained were subdivided into (i) those receiving first-line chemotherapy with or without irradiation, and (ii) those receiving second-line chemotherapy. All patients had Stage III or IV disease. Correlations are summarized in Table III. A positive correlation was obtained between in vitro sensitivity and in vivo response in 8/8 patients from the group receiving first-line chemotherapy, either as a single agent or in combination. Six of the 8 responses were complete, one was partial and one patient failed to show any response to thiotepa, which also was not cytotoxic against her tumour cells in vitro.
In patients receiving second-line chemotherapy, 3 showed both in vitro sensitivity and clinical response to the second-line agents used, which included vinblastine and treosulfan; one was resistant to cyclophosphamide in vitro and failed to show any clinical response. Three patients showed in vitro sensitivity and failed to show cinoma. The drugs in the lower-activity categories have also been found effective in evoking clinical responses in some this study indi-patients, with the exception of vinblastine, system used is which is clinically ineffective (Young et al., individual varia-1974) . Thus the in vitro system seems vities of human capable of predicting those agents which In the first-line are likely to be useful in the treatment of -elation between ovarian carcinoma. n vivo response Phosphoramide mustard, the metabo- Specimens were found to exhibit different sensitivities to 6 alkylating agents; complete resistance or sensitivity was rare. These findings parallel those made on the sensitivity of mouse L1210 leukaemic cells to alkylating agents (Schabel et al., 1978) and belie the belief that sensitivity to alkylating agents is an all-or-none phenomenon. In this study it was found that tumours from patients treated with thiotepa showed greater resistance to phosphoramide mustard than did tumours from untreated patients, which parallels the findings that cyclophosphamide-resistant L1210 leukaemia cells showed a 10-100-fold increase in resistance to thiotepa (Schabel et al., 1978) . The in vitro findings of this study, together with the observation that the toxicity of alkylating agents in combination is not always additive (Schabel et al., 1978) suggests that there may be a role for the combined use of alkylating agents in the treatment of advanced ovarian carcinoma. The apparently greater sensitivity of poorly differentiated tumours to cyclophosphamide may also be of clinical relevance.
Actinomycin D was found to be the most effective antibiotic, as well as one of the most effective agents in vitro. The concentration of 5 x 10-10 mg/ml which was tested was many times less than the peak plasma concentration achievable in humans of 7-5 x 10-5 mg/ml (Tattersall et al., 1975) but this was still sufficient to produce > 90% inhibition in most specimens tested. The drug would seem to have considerable potential, but in animal models it has been shown that, whilst cytotoxic in vitro (10-4-10-6 mg/ml) it enhanced tumour growth in vivo (Wilson, 1976) . The drug has not been used as a single agent in the treatment of ovarian carcinoma, but has been used with 5-fluorouracil and cyclophosphamide, when it was felt that it was merely adding to toxicity (Barlow & Piver, 1977) . The observation that the sensitivity to actinomycin D decreased after treatment with FAT suggests that the agent may be making a useful contribution to cell kill.
The sensitivity of 42% of tumours to hexamethylmelamine was of interest since, although the exact mechanism is unknown, it is thought to require activation in vivo, possibly involving N-demethylation by hepatic microsomes (Rutty & Connors, 1977; Rutty et al., 1978) . The results suggest either that the drug can exert some cytotoxic effect in its native form, or that some tumour cells are capable of metabolizing the drug to an active form. Procarbazine, another drug which requires in vivo activation, never showed in vitro activity. Although warfarin has been suggested as having a direct anti-tumour effect (Hilgard & Thornes, 1976) we found no in vitro activity against ovarian tumour cells. Progestogens, as has been suggested (Briggs et al., 1967; Malkasian et al., 1977) were found to show some useful activity in a small proportion of tumours, but no in vivo data are available on the relevant patients for comparison. Methylprednisolone acetate, again thought to be capable of a direct anti-tumour effect (Liebermann et al., 1977) was found to have some slight activity.
Considerable interest has been centred on the use of the clonogenic assay for in vitro screening of the drug sensitivity of human ovarian tumours (Alberts et al., 1980) . In the clonogenic assay the chemosensitivity of the "stem-cell" population of the tumour is specifically determined, whereas in a monolayer of tumour cells the chemosensitivity of the total dividing cell population is measured. In advanced ovarian cancer, where rapid debulking is important, it may be that the latter assay is of more relevance, the chemosensitivity of the "stem-cell" population becoming more important in the minimum ( < 2 cm diameter) or microscopic residual-disease situation. Preliminary experiments using cell lines indicate that the clonogenic and monolayer assays can give similar results for a particular drug (Wilson et al., 1981, unpublished data) . The monolayer system, with its potential for multiple drug screening, ease of performance and quantitation, may therefore provide a useful tool for the in vitro study of the drug sensitivity of human ovarian tumours.
